Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orforglipron Phase 2 in Type 2 Diabetes
NCT05048719Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of orforglipron in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Sep 2021; status: completed.
02
Drugs
orforglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05048719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05048719.